These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38154665)

  • 1. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review.
    Silverberg JI; Boguniewicz M; Quintana FJ; Clark RA; Gross L; Hirano I; Tallman AM; Brown PM; Fredericks D; Rubenstein DS; McHale KA
    J Allergy Clin Immunol; 2024 Jul; 154(1):1-10. PubMed ID: 38154665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
    Eichenfield LF; Silverberg JI; Hebert AA; Chovatiya R; Brown PM; McHale KA; Rubenstein DS; Tallman AM
    J Drugs Dermatol; 2024 Feb; 23(2):23-28. PubMed ID: 38306128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
    Bissonnette R; Stein Gold L; Rubenstein DS; Tallman AM; Armstrong A
    J Am Acad Dermatol; 2021 Apr; 84(4):1059-1067. PubMed ID: 33157177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
    Smith SH; Jayawickreme C; Rickard DJ; Nicodeme E; Bui T; Simmons C; Coquery CM; Neil J; Pryor WM; Mayhew D; Rajpal DK; Creech K; Furst S; Lee J; Wu D; Rastinejad F; Willson TM; Viviani F; Morris DC; Moore JT; Cote-Sierra J
    J Invest Dermatol; 2017 Oct; 137(10):2110-2119. PubMed ID: 28595996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapinarof Cream 1%: First Approval.
    Keam SJ
    Drugs; 2022 Jul; 82(11):1221-1228. PubMed ID: 35939180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.
    Bobonich M; Gorelick J; Aldredge L; Bruno MJ; DiRuggiero D; Martin G; Tallman AM; Gold LS
    J Drugs Dermatol; 2023 Aug; 22(8):779-784. PubMed ID: 37556512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.
    Furue M; Hashimoto-Hachiya A; Tsuji G
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural Compounds Tapinarof and
    Tsuji G; Hashimoto-Hachiya A; Matsuda-Taniguchi T; Takai-Yumine A; Takemura M; Yan X; Furue M; Nakahara T
    Front Immunol; 2022; 13():745997. PubMed ID: 35663970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis.
    Vu YH; Hashimoto-Hachiya A; Takemura M; Yumine A; Mitamura Y; Nakahara T; Furue M; Tsuji G
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapinarof to treat psoriasis.
    Rodríguez Baisi K; Tollefson M
    Drugs Today (Barc); 2020 Aug; 56(8):515-530. PubMed ID: 33025947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
    Armstrong AW; McConaha JL
    J Manag Care Spec Pharm; 2023 Dec; 29(12-a Suppl):S2-S14. PubMed ID: 38014659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
    Armstrong AW; McConaha JL
    J Manag Care Spec Pharm; 2023 Dec; 29(12-a Suppl):S1-S13. PubMed ID: 38051146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
    Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
    N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
    Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
    J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The aryl hydrocarbon receptor as the target structure for new drugs in psoriasis and atopic dermatitis].
    Merk HF
    Hautarzt; 2019 Dec; 70(12):942-947. PubMed ID: 31728551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
    Bissonnette R; Vasist LS; Bullman JN; Collingwood T; Chen G; Maeda-Chubachi T
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):524-531. PubMed ID: 29389078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapinarof cream for the topical treatment of plaque psoriasis in adults.
    Prieto K; Duong JQ; Feldman SR
    Expert Rev Clin Immunol; 2024 Apr; 20(4):327-337. PubMed ID: 38117596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
    Silverberg JI; Eichenfield LF; Hebert AA; Simpson EL; Stein Gold L; Bissonnette R; Papp KA; Browning J; Kwong P; Korman NJ; Brown PM; Rubenstein DS; Piscitelli SC; Somerville MC; Tallman AM; Kircik L
    J Am Acad Dermatol; 2024 Sep; 91(3):457-465. PubMed ID: 38777187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
    Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
    J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.
    Bissonnette R; Saint-Cyr Proulx E; Jack C; Maari C
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1168-1174. PubMed ID: 36708084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.